Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat

Metabolism: Clinical and Experimental

Volumn 50, Issue 8, 2001, Pages 963-971

  Dana, Sharon L ^a,b   Hoener, Patricia A ^a,b   Bilakovics, James M ^a,b   Crombie, Diane L ^a,b   Ogilvie, Kathleen M ^a,b   Kauffman, Raymond F ^a,b   Mukherjee, Ranjan ^a,b   Paterniti, James R ^a,b  

^a LIGAND PHARMACEUTICALS INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A OXIDASE; APOLIPOPROTEIN C3; ENOYL COENZYME A HYDRATASE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 4; GW 2331; INSULIN; LIGAND; MESSENGER RNA; MITOGEN ACTIVATED PHOSPHOKINASE PHOSPHATASE 1; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RETINOID X RECEPTOR; ROSIGLITAZONE; THIAZOLE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC OBESITY; DRUG EFFECT; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; LIVER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; RAT STRAIN; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034869222     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2001.24870     Document Type: Article

References (49)

1. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
2. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones
3. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
4. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid
5. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPAR-gamma1 and activation with retinoid X receptor agonists and antagonists
6. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
7. Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators
8. RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo
9. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs)
10. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: A potential physiologic basis for their mode of action
11. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III
12. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates
13. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III
14. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins lipase in vivo
15. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates
16. Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene
17. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene
18. Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl- CoA dehydrogenase
19. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
20. The metabolic effects of troglitazone in non-insulin-dependent diabetes (NIDDM)
21. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene
22. Glucocorticoids repress induction by thiazolidinediones, fibrates, and fatty acids of phosphoenolpyruvate carboxykinase gene expression in adipocytes
23. Multihormonal regulation of phosphoenolpyruvate carboxykinase gene transcription. The dominant role of insulin
24. A retinoic acid response element is part of a pleiotropic domain in the phosphoenolpyruvate carboxykinase gene
25. Troglitazone inhibits expression of the phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanism
26. Insulin signal transduction through protein kinase cascades
27. Blunting of the immediate-early gene and mitogenic response in hepatectomized type 1 diabetic animals
28. Insulin-induced mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) attenuates insulin-stimulated MAP kinase activity: A mechanism for the feedback inhibition of insulin signaling
29. Protein phosphatases and the regulation of MAP kinase activity
30. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
31. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor
32. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats
33. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization
34. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
35. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
36. Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element
37. Opposing actions of Fos and Jun on transcription of the phosphoenolpyruvate carboxykinase (GTP) gene. Dominant negative regulation by Fos
38. Isolation and characterization of a human dual specificity protein-tyrosine phosphatase gene
39. Osmotic loading of neutralizing antibodies demonstrates a role for protein-tyrosine phosphatase 1B in negative regulation of the insulin action pathway
40. Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling
41. Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR
42. Modulation of insulin signal transduction by eutopic overexpression of the receptor-type protein-tyrosine phosphatase LAR
43. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatse-1B gene
44. Hyperosmotic induction of the mitogen-activated protein kinase phosphatase MKP-1 in H4IE rat hepatoma cells
45. Protein kinase signaling pathway triggered by cell swelling and involved in the activation of glycogen synthase and acetyl-CoA carboxylase in isolated rat hepatocytes
46. Modulation of phosphoenolpyruvate carboxykinase mRNA levels by the hepatocellular hydration state
47. Disruption of the erp/mkp-1 gene does not affect mouse development: Normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts
48. Does mitogen-activated-protein kinase have a role in insulin action? The cases of for and against
49. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the apperance of two new high density lipoprotein size subclasses